P53 proteins with altered tetramerization domains

Details P53 proteins with altered tetramerization domains P53 proteins with altered tetramerization domains

1994-11-28

1996-11-12

Wax, Robert A.

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

536 234, 530350, 514 44, A61K 3170, C07H 2104, C12P 2104, C07K 1900

Patent

active

055739253

ABSTRACT:
The present invention provides p53 proteins with altered tetramerization domains that retain wild-type p53 function, and the ability to form tetramers and have at least one of the following characteristics: (1) do not hetero-oligomerize with wild-type p53 or tumor-derived p53 mutants, and (2) restricted DNA binding specificity from an alteration in the way that the tetramerization domain orients the DNA binding domains of a p53 tetramer relative to one another. The invention also provides nucleic acids encoding the above proteins and methods of enhancing the cellular response to DNA damaging agents, treating diseases characterized by abnormal cell proliferation, and inducing immune tolerance to facilitate transplants and treatment of autoimmune disease, by administration of proteins of the invention or nucleic acid sequences encoding the proteins of the invention.

REFERENCES:
patent: 5362623 (1994-11-01), Vogelstein et al.
Reed, M. et al. (1993) "p53 domains: suppression, transformation, and transactivation" Gene Expression 3(1):95-107.
Sellers, J. W. et al. (1989) "Changing Fos oncoprotein to a Jun-independent DNA-binding protein with GCN4 dimerization specificity by swapping `leucine zippers`" Nature 341:74-76.
Oertel-Buchheit, P. et al. (1993) "Spacing requirements between LexA operator half-sites can be relaxed by fusing the LexA DNA binding domain with some alternative dimerization domains" J. Mol. Biol. 229:1-7.
Miller, C. W. et al. (1993) "Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription" Oncogene 8:1815-1824.
Iwabuchi, K. et al. (1993) "Use of the two-hybrid system to identify the domain of p53 involved in oligomerization" Oncogene 8:1693-1696.
A. Ferre-D'Amare et al, "Recognition by Max of its Cognate DNA Through a Dimeric b/HLH/Z Domain", Nature, 363:38-45 (May 6, 1993).
C. Vinson et al, "Scissors-Grip Model for DNA Recognition by a Family of Leucine Zipper Proteins", Science, 246:911-916 (Nov. 17, 1989).
S. Alberti et al, "Genetic Analysis of the Leucine Heptad Repeats of Lac Repressor: Evidence for a 4-helical Bundle", EMBO J., 12:3227-3236 (1993).
T. Halazonetis et al, "Conformational Shifts Propagate from the Oligomerization Domain of p53 to its Tetrameric DNA Binding Domain and Restore DNA Binding to Select p53 Mutants", EMBO J., 12(13):5057-5064 (Dec., 1993) [Halazonetis I].
T. Halazonetis et al, "Wild-Type p53 Adopts a `Mutant`-Like Conformation when Bound to DNA", EMBO J., 12(3):1021-1028 (Mar., 1993) [Halazonetis II].
T. Halazonetis et al, "c-Jun Dimerizes with itself and with c-Fos, Forming Complexes of Different DNA Binding Affinities", Cell, 55:917-924 (Dec. 2, 1988) [Halazonetis III].
Y. Wang et al, "p53 Domains: Identification and Characterization of Two Autonomous DNA-Binding Regions", Genes & Development, 7:2575-2586 (Dec., 1993) [Wang I].
P. Wang et al, "p53 Domains: Structure, Oligomerization, and Transformation", Mol. Cell. Biol., 14(8):5182-5191 (Aug., 1994) [Wang II].
T. Hupp et al, "Regulation of the Specific DNA Binding Function of p53", Cell, 71:875-886 (Nov. 27, 1992) [Hupp I].
T. Hupp et al, "Activation of the Cryptic DNA Binding Function of Mutant Forms of p53", Nucl. Acids Res., 21(14):3167-3174 (Jul. 14, 1993) [Hupp III].
T. Fujiwara et al, "A Retroviral Wild-type p53 Expression Vector Penetrates Human Lung Cancer Spheroids and Inhibits Growth by Inducing Apoptosis", Cancer Res., 53:4129-4133 (Sep. 15, 1993) [Fujiwara I].
T. Fujiwara et al, "Induction of Chemosensitivity in Human Lung Cancer Cells in vivo by Adenovirus-Mediated Transfer of the Wild-Type p53 Gene", Cancer Res., 54:2287-2291 (May 1, 1994) [Fujiwara II].
G. Shaulsky et al, "Nuclear Localization is Essential for the Activity of p53 Protein", Oncogene, 6:2056-2065 (Nov., 1991) [Shaulsky I].
G. Shaulsky et al, "Nuclear Accumulation of p53 Protein is Mediated by Several Nuclear Localization Signals and Plays a Role in Tumorigenesis", Mol. Cell. Biol., 10:(12):6565-6577 (Dec., 1990) [Shaulsky II].
J. Oliner et al, "Amplification of a Gene Encoding a p53-Associated Protein in Human Sarcomas", Nature, 358:80-83 (Jul. 2, 1992) [Oliner I].
J. Oliner et al, "Oncoprotein MDM2 Conceals the Activation Domain of Tumor Suppressor p53", Nature, 362:857-860 (Apr. 29, 1993) [Oliner II].
K. Zhang et al, "Drosophila Homolog of the Mammalian jun Oncogene is Expressed During Embryonic Development and Activates Transcription in Mammalian Cells", Proc. Natl. Acad. Sci. USA, 87:6281-6285 (Aug., 1990) [Zhang I].
L. Zhang et al, "Antibody-Promoted Dimerization Bypasses the Regulation of DNA Binding by the Heme Domain of the Yeast Transcriptional Activator HAP1", Proc. Natl. Acad. Sci. USA, 90:2851-2855 (Apr., 1993) [Zhang II].
J. Chen et al, "Heterogeneity of Transcriptional Activity of Mutant p53 Proteins and p53 DNA Target Sequences", Oncogene, 8:2159-2166 (Aug. 1993) [Chen I].
J. Chen et al, "Mapping of the p53 and mdm-2 Interaction Domains", Mol. Cell. Biol., 13(7):4107-4114 (Jul., 1993) [Chen II].
L. Diller et al, "p53 Functions as a Cell Cycle Control Protein in Osteosarcomas", Mol. Cell. Biol., 10(11):5772-5781 (Nov., 1990).
C. Harris, "p53: At the Crossroads of Molecular Carcinogenesis and Risk Assessment", Science, 262:1980-1981 (Dec. 24, 1993).
R. Zakut-Houri et al, "Human p53 Cellular Tumor Antigen: cDNA Sequence and Expression in COS Cells", `EMBO J., 4(5):1251-1255 (May, 1985).
T. Soussi et al, "Structural Aspects of the p53 Protein in Relation to Gene Evolution", Oncogene, 5:945-952 (Jul. 1990).
J. Pietenpol et al, "Sequence-Specific Transcriptional Activation is Essential for Growth Suppression by p53", Proc. Natl. Acad. Sci. USA, 91:1998-2002 (Mar., 1994).
S. Kraiss et al, "Oligomerization of Oncoprotein p53", J. Virol., 62(12):4737-4744 (Dec., 1988).
T. Friedmann, "Gene Therapy of Cancer Through Restoration of Tumor-Suppressor Functions", Cancer Supplement, 70(6):1810-1817 (Sep. 15, 1992).
P. Friedman et al, "The p53 Protein is an Unusually Shaped Tetramer that Binds Directly to DNA", Proc. Natl. Acad. Sci. USA, 90:3319-3323 (Apr., 1993).
P. Hainaut et al, "Analysis of p53 Quaternary Structure in Relation to Sequence-Specific DNA Binding", Oncogene, 9:299-303 (Jan., 1994).
W. El-Deiry et al, "WAF1, a Potential Mediator of p53 Tumor Suppression", Cell, 75:817-825 (Nov. 19, 1993).
X. Wu et al, "The p53-mdm-2 Autoregulatory Feedback Loop", Genes & Development, 7:1126-1132 (Jul., 1993).
M. Kastan et al, "A Mammalian Cell Cycle Checkpoint Pathway Utilizing p53 and GADD45 is Defective in Ataxia-Telangiectasia", Cell, 71:587-597 (Nov. 13, 1992).
N. Pavletich et al, "The DNA-Binding Domain of p53 Contains the Four Conserved Regions and the Major Mutation Hot Spots", Genes & Development, 7:2556-2564 (Dec., 1993).
S. Fields et al, "Presence of a Potent Transcription Activating Sequence in the p53 Protein", Science, 249:1046-1049 (Aug. 31, 1990).
J. Bargonetti et al, "Site-Specific Binding of Wild-Type p53 to Cellular DNA is Inhibited by SV40 T Antigen and Mutant p53", Genes & Development, 6:1886-1898 (Oct., 1992).
C. Finlay et al, "The p53 Proto-Oncogene can Act as a Suppressor of Transformation", Cell, 57:1083-1093 (Jun. 30, 1989).
D. Eliyahu et al, "Wild-Type p53 can Inhibit Oncogene-Mediated Focus Formation", Proc. Natl. Acad. Sci. USA, 86:8763-8767 (Nov., 1989).
S. Baker et al, "Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53", Science, 249:912-915 (Aug. 24, 1990).
W. Mercer et al, "Negative Growth Regulation in a Glioblastoma Tumor Cell Line that Conditionally Expresses Human Wild-Type p53", Proc. Natl. Acad. Sci. USA, 87:6166-6170 (Aug., 1990).
W. Isaacs et al, "Wild-Type p53 Suppresses Growth of Human Prostate Cancer Cells Containing Mutant p53 Alleles", Cancer Res., 51:4716-4720 (Sep. 1, 1991).
S. Kern et al, "Oncogenic Forms of p53 Inhibit p53-Regulated Gene Expression", Science, 256:827-830 (May 8, 1992).
E. Yonish-Rouach et al, "p53-Mediated Cell Death: Relationship to Cell Cycle Control", Mol. Cell. Biol., 13(3):1415-1423 (Mar., 1993).
S. Lowe et al, "p53-Dependent Apoptosis Modulates the Cytotoxicity of Antic

Affiliated with

Also associated with

Rating

P53 proteins with altered tetramerization domains does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with P53 proteins with altered tetramerization domains, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and P53 proteins with altered tetramerization domains will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-561753